Publicacions en col·laboració amb investigadors/es de Universitat Autònoma de Barcelona (7)

2023

  1. Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis

    Brain Communications, Vol. 5, Núm. 2

2022

  1. Seroprevalence of SARS‐CoV‐2 in a Cohort of Patients with Multiple Sclerosis under Disease‐Modifying Therapies

    Journal of Clinical Medicine, Vol. 11, Núm. 9

2021

  1. Assessing blood-based biomarkers to define a therapeutic window for natalizumab

    Journal of Personalized Medicine, Vol. 11, Núm. 12

2019

  1. Mitochondrial m.13513G > A Point Mutation in ND5 in a 16-Year-Old Man with Leber Hereditary Optic Neuropathy Detected by Next-Generation Sequencing

    JOURNAL OF PEDIATRIC GENETICS, Vol. 8, Núm. 4, pp. 231-234

  2. Th1Th17CM lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment

    Mediators of Inflammation, Vol. 2019

2018

  1. Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients

    CNS Neuroscience and Therapeutics, Vol. 24, Núm. 12, pp. 1175-1184

2011

  1. Interferon beta-1b for the treatment of primary progressive multiple sclerosis: Five-year clinical trial follow-up

    Archives of Neurology, Vol. 68, Núm. 11, pp. 1421-1427